What is Ipamorelin?

Ipamorelin is a research peptide in the GH Secretagogue class. Selective ghrelin-receptor agonist; GH-specific with minimal cortisol or prolactin effect. It is studied at per-dose ranges of 200–300 mcg × 2–3 / day (4–6 mg weekly), administered 2–3× daily sc over cycles of 12 weeks on / 4 off. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Pentapeptide GHS. Acts on GHS-R1a without appreciable effect on cortisol, prolactin, or appetite at standard research doses.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Ipamorelin work?

Primary mechanism: Selective ghrelin-receptor agonist; GH-specific with minimal cortisol or prolactin effect. Research on Ipamorelin implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Ipamorelin remain areas of active investigation; several proposed effects within the GH Secretagogue class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Ipamorelin dosage & protocol

Reference protocol for Ipamorelin (research context only, drawn from published literature):

  • Per dose: 200–300 mcg × 2–3 / day
  • Weekly total: 4–6 mg
  • Frequency: 2–3× daily SC
  • Cycle: 12 weeks on / 4 off

Stacking Ipamorelin

Commonly referenced pairing with Ipamorelin: CJC-1295, Tesamorelin. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Ipamorelin stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Ipamorelin — common questions

What is Ipamorelin and what is it used for in research?
Ipamorelin is classified within the GH Secretagogue group. Pentapeptide GHS. Acts on GHS-R1a without appreciable effect on cortisol, prolactin, or appetite at standard research doses. Research applications focus on the pathways outlined below. All references on this page describe published research only — Ipamorelin is supplied for in-vitro and laboratory use, not for human consumption.
How does Ipamorelin work?
Primary mechanism: Selective ghrelin-receptor agonist; GH-specific with minimal cortisol or prolactin effect. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Ipamorelin remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Ipamorelin research dose?
Published research protocols for Ipamorelin describe per-dose ranges of 200–300 mcg × 2–3 / day, with a weekly total near 4–6 mg, administered 2–3× daily sc. Typical cycle: 12 weeks on / 4 off. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Ipamorelin in Thailand?
Ipamorelin is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Ipamorelin be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
  2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.